Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 4/2017

01-08-2017 | Original Paper

The role of hERG1 ion channels in epithelial-mesenchymal transition and the capacity of riluzole to reduce cisplatin resistance in colorectal cancer cells

Author: Angelo Fortunato

Published in: Cellular Oncology | Issue 4/2017

Login to get access

Abstract

Purpose

The transition of cells from the epithelial to the mesenchymal state (EMT) plays an important role in tumor progression. EMT allows cells to acquire mobility, stem-like behavior and resistance to apoptosis and drug treatment. These features turn EMT into a central process in tumor biology. Ion channels are attractive targets for the treatment of cancer since they play critical roles in controlling a wide range of physiological processes that are frequently deregulated in cancer. Here, we investigated the role of ether-a-go-go-related 1 (hERG1) ion channels in the EMT of colorectal cancer cells.

Methods

We studied the epithelial-mesenchymal profile of different colorectal cancer-derived cell lines and the expression of hERG1 potassium channels in these cell lines using real-time PCR. Next, we knocked down hERG1 expression in HCT116 cells using lentivirus mediated RNA interference and characterized the hERG1 silenced cells in vitro and in vivo. Finally, we investigated the capacity of riluzole, an ion channel-modulating drug used in humans to treat amyotrophic lateral sclerosis, to reduce the resistance of the respective colorectal cancer cells to the chemotherapeutic drug cisplatin.

Results

We found that of the colorectal cancer-derived cell lines tested, HCT116 showed the highest mesenchymal profile and a high hERG1 expression. Subsequent hERG1 expression knockdown induced a change in cell morphology, which was accompanied by a reduction in the proliferative and tumorigenic capacities of the cells. Notably, we found that hERG1expression knockdown elicited a reversion of the EMT profile in HCT116 cells with a reacquisition of the epithelial-like profile. We also found that riluzole increased the sensitivity of HCT116 cisplatin-resistant cells to cisplatin.

Conclusions

Our data indicate that hERG1 plays a role in the EMT of colorectal cancer cells and that its knockdown reduces the proliferative and tumorigenic capacities of these cells. In addition, we conclude that riluzole may be used in combination with cisplatin to reduce chemo-resistance in colorectal cancer cells.
Appendix
Available only for authorised users
Literature
1.
J. Guinney, R. Dienstmann, X. Wang, A. de Reynies, A. Schlicker, C. Soneson, L. Marisa, P. Roepman, G. Nyamundanda, P. Angelino, B.M. Bot, J.S. Morris, I.M. Simon, S. Gerster, E. Fessler, E.M.F. De Sousa, E. Missiaglia, H. Ramay, D. Barras, K. Homicsko, D. Maru, G.C. Manyam, B. Broom, V. Boige, B. Perez-Villamil, T. Laderas, R. Salazar, J.W. Gray, D. Hanahan, J. Tabernero, R. Bernards, S.H. Friend, P. Laurent-Puig, J.P. Medema, A. Sadanandam, L. Wessels, M. Delorenzi, S. Kopetz, L. Vermeulen, S. Tejpar, The consensus molecular subtypes of colorectal cancer. Nat Med 21, 1350–1356 (2015)CrossRefPubMedPubMedCentral
2.
M.M. Hahn, R.M. de Voer, N. Hoogerbrugge, M.J. Ligtenberg, R.P. Kuiper, A.G. van Kessel, The genetic heterogeneity of colorectal cancer predisposition - guidelines for gene discovery. Cell Oncol 39, 491–510 (2016)CrossRef
3.
A. Loboda, M.V. Nebozhyn, J.W. Watters, C.A. Buser, P.M. Shaw, P.S. Huang, L. Van't Veer, R.A. Tollenaar, D.B. Jackson, D. Agrawal, H. Dai, T.J. Yeatman, EMT is the dominant program in human colon cancer. BMC Med Genet 4, 9 (2011)
4.
5.
A. Sathyanarayanan, K.S. Chandrasekaran, D. Karunagaran, microRNA-145 modulates epithelial-mesenchymal transition and suppresses proliferation, migration and invasion by targeting SIP1 in human cervical cancer cells. Cell Oncol 40, 119–131 (2017)CrossRef
6.
S. Bugide, V.K. Gonugunta, V. Penugurti, V.L. Malisetty, R.K. Vadlamudi, B. Manavathi, HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation. Cell Oncol 40, 133–144 (2017)
7.
J.P. Thiery, J.P. Sleeman, Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7, 131–142 (2006)CrossRefPubMed
8.
H. Hugo, M.L. Ackland, T. Blick, M.G. Lawrence, J.A. Clements, E.D. Williams, E.W. Thompson, Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression. J Cell Physiol 213, 374–383 (2007)CrossRefPubMed
9.
B. Baum, J. Settleman, M.P. Quinlan, Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol 19, 294–308 (2008)CrossRefPubMed
10.
J. Yang, R.A. Weinberg, Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev Cell 14, 818–829 (2008)CrossRefPubMed
11.
K. Polyak, R.A. Weinberg, Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer 9, 265–273 (2009)CrossRefPubMed
12.
S. Corallino, M.G. Malabarba, M. Zobel, P.P. Di Fiore, G. Scita, Epithelial-to-mesenchymal plasticity harnesses endocytic circuitries. Front Oncol 5, 45 (2015)CrossRefPubMedPubMedCentral
13.
14.
J.H. Taube, J.I. Herschkowitz, K. Komurov, A.Y. Zhou, S. Gupta, J. Yang, K. Hartwell, T.T. Onder, P.B. Gupta, K.W. Evans, B.G. Hollier, P.T. Ram, E.S. Lander, J.M. Rosen, R.A. Weinberg, S.A. Mani, Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A 107, 15449–15454 (2010)CrossRefPubMedPubMedCentral
15.
16.
J.R. Schwarz, C.K. Bauer, Functions of erg K+ channels in excitable cells. J Cell Mol Med 8, 22–30 (2004)CrossRefPubMed
17.
L.A. Pardo, D. del Camino, A. Sanchez, F. Alves, A. Bruggemann, S. Beckh, W. Stuhmer, Oncogenic potential of EAG K(+) channels. EMBO J 18, 5540–5547 (1999)CrossRefPubMedPubMedCentral
18.
B. Hemmerlein, R.M. Weseloh, F. Mello de Queiroz, H. Knotgen, A. Sanchez, M.E. Rubio, S. Martin, T. Schliephacke, M. Jenke, R. Heinz Joachim, W. Stuhmer, L.A. Pardo, Overexpression of Eag1 potassium channels in clinical tumours. Mol Cancer 5, 41 (2006)CrossRefPubMedPubMedCentral
19.
M. Spitzner, J. Ousingsawat, K. Scheidt, K. Kunzelmann, R. Schreiber, Voltage-gated K+ channels support proliferation of colonic carcinoma cells. FASEB J 21, 35–44 (2007)CrossRefPubMed
20.
21.
22.
S.M. Huber, G.S. Braun, S. Segerer, R.W. Veh, M.F. Horster, Metanephrogenic mesenchyme-to-epithelium transition induces profound expression changes of ion channels. Am J Physiol Renal Physiol 279, F65–F76 (2000)PubMed
23.
J. Hu, K. Qin, Y. Zhang, J. Gong, N. Li, D. Lv, R. Xiang, X. Tan, Downregulation of transcription factor Oct4 induces an epithelial-to-mesenchymal transition via enhancement of Ca2+ influx in breast cancer cells. Biochem Biophys Res Commun 411, 786–791 (2011)CrossRefPubMed
24.
F.M. Davis, A.A. Peters, D.M. Grice, P.J. Cabot, M.O. Parat, S.J. Roberts-Thomson, G.R. Monteith, Non-stimulated, agonist-stimulated and store-operated Ca2+ influx in MDA-MB-468 breast cancer cells and the effect of EGF-induced EMT on calcium entry. PLoS One 7, e36923 (2012)CrossRefPubMedPubMedCentral
25.
I. Restrepo-Angulo, C. Sanchez-Torres, J. Camacho, Human EAG1 potassium channels in the epithelial-to-mesenchymal transition in lung cancer cells. Anticancer Res 31, 1265–1270 (2011)PubMed
26.
A. Schwab, C. Stock, Ion channels and transporters in tumour cell migration and invasion. Philos Trans R Soc Lond Ser B Biol Sci 369, 20130102 (2014)CrossRef
27.
O. Crociani, F. Zanieri, S. Pillozzi, E. Lastraioli, M. Stefanini, A. Fiore, A. Fortunato, M. D'Amico, M. Masselli, E. De Lorenzo, L. Gasparoli, M. Chiu, O. Bussolati, A. Becchetti, A. Arcangeli, hERG1 channels modulate integrin signaling to trigger angiogenesis and tumor progression in colorectal cancer. Sci Rep 3, 3308 (2013)CrossRefPubMedPubMedCentral
28.
B. Hille, Ion channels of excitable membranes, 3rd edn. (Sinauer, Sunderland, Mass, 2001)
29.
N.M. Hogan, R.M. Dwyer, M.R. Joyce, M.J. Kerin, Mesenchymal stem cells in the colorectal tumor microenvironment: Recent progress and implications. Int J Cancer 131, 1–7 (2012)CrossRefPubMed
30.
J. Lam, N. Coleman, A.L. Garing, H. Wulff, The therapeutic potential of small-conductance KCa2 channels in neurodegenerative and psychiatric diseases. Expert Opin Ther Targets 17, 1203–1220 (2013)CrossRefPubMedPubMedCentral
31.
A. Sankaranarayanan, G. Raman, C. Busch, T. Schultz, P.I. Zimin, J. Hoyer, R. Kohler, H. Wulff, Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. Mol Pharmacol 75, 281–295 (2009)CrossRefPubMed
32.
E. Lastraioli, L. Guasti, O. Crociani, S. Polvani, G. Hofmann, H. Witchel, L. Bencini, M. Calistri, L. Messerini, M. Scatizzi, R. Moretti, E. Wanke, M. Olivotto, G. Mugnai, A. Arcangeli, herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells. Cancer Res 64, 606–611 (2004)CrossRefPubMed
33.
R. Schonherr, B. Rosati, S. Hehl, V.G. Rao, A. Arcangeli, M. Olivotto, S.H. Heinemann, E. Wanke, Functional role of the slow activation property of ERG K+ channels. Eur J Neurosci 11, 753–760 (1999)CrossRefPubMed
34.
35.
A. Fortunato, L. Gasparoli, S. Falsini, L. Boni, A. Arcangeli, An analytical method for the quantification of hERG1 channel gene expression in human colorectal cancer. Diagn Mol Pathol 22, 215–221 (2013)CrossRefPubMed
36.
T.C. Chou, P. Talalay, Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58, 621–681 (2006) Erratum in: Pharmacol. Rev. 59, 124 (2007)CrossRefPubMed
37.
E.L. Lee, Y. Hasegawa, T. Shimizu, Y. Okada, IK1 channel activity contributes to cisplatin sensitivity of human epidermoid cancer cells. Am J Physiol Cell Physiol 294, C1398–C1406 (2008)CrossRefPubMed
38.
R. Paduch, The role of lymphangiogenesis and angiogenesis in tumor metastasis. Cell Oncol 39, 397–410 (2016)CrossRef
39.
L. Guasti, O. Crociani, E. Redaelli, S. Pillozzi, S. Polvani, M. Masselli, T. Mello, A. Galli, A. Amedei, R.S. Wymore, E. Wanke, A. Arcangeli, Identification of a posttranslational mechanism for the regulation of hERG1 K+ channel expression and hERG1 current density in tumor cells. Mol Cell Biol 28, 5043–5060 (2008)CrossRefPubMedPubMedCentral
40.
41.
S. Dasari, P.B. Tchounwou, Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol 740, 364–378 (2014)CrossRefPubMed
42.
J.W. Albers, V. Chaudhry, G. Cavaletti and R.C. Donehower, Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev, CD005228 (2014)
43.
J. Killestein, N.F. Kalkers, C.H. Polman, Glutamate inhibition in MS: The neuroprotective properties of riluzole. J Neurol Sci 233, 113–115 (2005)CrossRefPubMed
Metadata
Title
The role of hERG1 ion channels in epithelial-mesenchymal transition and the capacity of riluzole to reduce cisplatin resistance in colorectal cancer cells
Author
Angelo Fortunato
Publication date
01-08-2017
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 4/2017
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-017-0328-6

Other articles of this Issue 4/2017

Cellular Oncology 4/2017 Go to the issue

Report

Progesterone suppresses the invasion and migration of breast cancer cells irrespective of their progesterone receptor status - a short report

Report

Tumor cells interact with red blood cells via galectin-4 - a short report

Original Paper

Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours

Original Paper

Association between epidermal growth factor receptor amplification and ADP-ribosylation factor 1 methylation in human glioblastoma

Original Paper

MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin

Review

A step-by-step microRNA guide to cancer development and metastasis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits